Biotech Earnings Preview: Mixed Results Send Stocks on Divergent Paths
Nuvation Bio and Sarepta shares tumble on disappointing preliminary results while Adaptive Biotechnologies surges on strong revenue beat.
/ 3 items
#ADPT↓
Adaptive Biotechnologies Partners with Pfizer on Immune Disease Research
Adaptive Biotechnologies signs two deals with Pfizer worth up to $890M to discover rheumatoid arthritis treatments and share immune system data for AI-powered drug development.
Adaptive: Why Analysts See It as a Dominant Force
Guggenheim rated ADPT a "Buy." It dominates blood cancer testing and will see major growth. "Shares are currently undervalued."